Durvalumab-based perioperative regimen is the first FDA-approved immunotherapy for muscle-invasive bladder cancer (MIBC), showing significant event-free and overall survival benefits in the ...

This durvalumab regimen significantly extended ... bringing the first perioperative immunotherapy to patients in the US with muscle-invasive bladder cancer and addressing a significant need ...

Enrolled patients were given three courses of durvalumab plus tremelimumab ... did not receive the third planned dose of ...

plus durvalumab. The duration of immunotherapy was 7.3 months. The median time to downstaging with immunotherapy was 7.2 months compared with 3 months in the UNOS-DS group and 4.7 months in an all ...

Dr. Matthew Galsky discusses the FDA approval of Imfinzi and chemo before and after surgery for muscle-invasive bladder ...

This durvalumab regimen significantly extended patients’ lives ... bringing the first perioperative immunotherapy to patients in the US with muscle-invasive bladder cancer and addressing a significant ...

Durvalumab was given to patients after finishing ... Once approved, Imfinzi could become the lead immunotherapy in early (stages 1-3) lung cancer, allowing it to leapfrog Keytruda, as Merck ...

2 "With this approval, we can now offer immunotherapy treatment to people ... license by AstraZeneca Canada Inc. 2 Cheng Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

ICI-based therapy included administration of any of the following drugs during treatment: Nivolumab, pembrolizumab, atezolizumab, ipilimumab, tremelimumab, durvalumab, or avelumab. Primary ...

AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to ...